About Recursion Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.recursion.com/
Frequently Asked Questions
What is the 52-week range for RXRX?
The 52-week high is $7.18 and the 52-week low is $2.77.
What is the P/E ratio for RXRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for RXRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -50.41%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -945.92%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.88.
Analyst Recommendation Trends
Wall Street analyst consensus for RXRX over the last few months:
Latest RXRX News
'HHS launches project to speed up clinical trials' - Axios
https://www.axios.com/2026/09/30/hhs-clinical-trials-redesign
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1.2% shift from the previous trading day.
Squeeze Watch: 10 Stocks With Over 33% Short Interest
Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
Analysts move HubSpot 29 places higher in power ranking
HubSpot sits 29 places higher at No. 57 in the Roundtable 100 this week.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.05, representing a +2.02% change from its previous close.
Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test
Goldman Sachs’ Neutral initiation of Tempus AI, Inc. (NASDAQ:TEM) on September 21 puts the company’s fastest-growing businesses under different tests: diagnostics offers visible near-term growth, while the data and applications segment faces renewal risk as several major contracts approach extensions over the next two years. The timing is notable because Tempus AI, Inc. (NASDAQ:TEM) announced […]
Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement
Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company’s shift toward an end-to-end, AI-enabled drug discovery and development platform. Kha
Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?
Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at US$3.83. Recent returns have been mixed over the past week and month. For context, Recursion Pharmaceuticals has delivered an 8.19% 1-day share price return and a 19.69% 7-day share price return, yet the total shareholder return over the past year is down 22%. This hints at short-term momentum building against a more difficult long-term backdrop and shifting views on the...
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Recursion Pharmaceuticals (NASDAQ:RXRX) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsNajat Khan...
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
2 Beaten-Down Stocks to Avoid Right Now
Don't catch a falling knife.
Oracle, Adobe Results In Focus As Earnings Season Winds Down
Stay ahead with Wall Street Week Ahead: key earnings (Oracle, Adobe, Kroger), IPOs & CPI/PPI data, plus volatility/dividend watch. See more here.
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Taylor Ben R | -5,396 | $3.41 | $18,400 |
| 2026-09-08 | Khan Najat | -22,408 | $3.5176 | $78,822 |
| 2026-09-01 | Borgeson Blake | -30,000 | $3.34 | $100,200 |
| 2026-08-17 | Khan Najat | -80,498 | $3.16 | $254,374 |
| 2026-08-17 | Hallett David | -26,657 | $3.16 | $84,236 |
| 2026-08-17 | Taylor Ben R | -25,018 | $3.16 | $79,057 |
| 2026-08-04 | Borgeson Blake | -30,000 | $3.25 | $97,500 |
| 2026-07-07 | Borgeson Blake | -40,000 | $3.9625 | $158,500 |
| 2026-07-01 | Dar Zavain | +5,109 | - | - |
| 2026-07-01 | Li Dean Y | +3,747 | - | - |
| 2026-06-18 | Bumpus Namandje | -3,963 | $3.18 | $12,602 |
| 2026-06-17 | Borgeson Blake | +88,424 | - | - |
| 2026-06-17 | Michor Franziska | +88,424 | - | - |
| 2026-06-17 | Sun Elaine D | +88,424 | - | - |
| 2026-06-17 | Dar Zavain | +88,424 | - | - |
| 2026-06-17 | Li Dean Y | +88,424 | - | - |
| 2026-06-17 | Bumpus Namandje | +88,424 | - | - |
| 2026-06-17 | HERSHBERG ROBERT | +88,424 | - | - |
| 2026-06-15 | Taylor Ben R | -5,396 | $3.15 | $16,997 |
| 2026-06-05 | Khan Najat | -23,588 | $3.5806 | $84,459 |
| 2026-06-05 | Gibson Christopher | -40,000 | - | - |
| 2026-06-05 | Gibson Christopher | -40,000 | $3.62 | $144,800 |
| 2026-06-05 | Gibson Christopher | +40,000 | - | - |
| 2026-06-03 | Bumpus Namandje | -4,386 | $3.54 | $15,526 |
| 2026-06-02 | Borgeson Blake | -30,000 | $3.68 | $110,400 |
| 2026-05-22 | Gibson Christopher | -40,000 | - | - |
| 2026-05-22 | Gibson Christopher | -40,000 | $3.08 | $123,200 |
| 2026-05-22 | Gibson Christopher | +40,000 | - | - |
| 2026-05-15 | Khan Najat | -62,701 | $3.04 | $190,611 |
| 2026-05-15 | Hallett David | -26,657 | $3.04 | $81,037 |
| 2026-05-15 | Gibson Christopher | -22,821 | $3.04 | $69,376 |
| 2026-05-15 | Taylor Ben R | -25,018 | $3.04 | $76,055 |
| 2026-05-07 | Gibson Christopher | -60,000 | - | - |
| 2026-05-07 | Gibson Christopher | -20,000 | - | - |
| 2026-05-07 | Gibson Christopher | -40,000 | $3.37 | $134,800 |
| 2026-05-07 | Gibson Christopher | +60,000 | - | - |
| 2026-05-05 | Borgeson Blake | -30,000 | $3.52 | $105,600 |
| 2026-04-22 | Gibson Christopher | -40,000 | - | - |
| 2026-04-22 | Gibson Christopher | -40,000 | $3.61 | $144,400 |
| 2026-04-22 | Gibson Christopher | +40,000 | - | - |
| 2026-04-07 | Gibson Christopher | -40,000 | - | - |
| 2026-04-07 | Gibson Christopher | -40,000 | $3.1 | $124,000 |
| 2026-04-07 | Gibson Christopher | +40,000 | - | - |
| 2026-04-07 | Borgeson Blake | -30,000 | $3.1 | $93,000 |
| 2026-04-06 | Taylor Ben R | -48,028 | $3.11 | $149,367 |
| 2026-04-01 | Dar Zavain | +4,902 | - | - |
| 2026-04-01 | Li Dean Y | +3,268 | - | - |
| 2026-03-23 | Gibson Christopher | -40,000 | - | - |
| 2026-03-23 | Gibson Christopher | -40,000 | $3.25 | $130,000 |
| 2026-03-23 | Gibson Christopher | +40,000 | - | - |
| 2026-03-17 | Taylor Ben R | -7,956 | $3.39 | $26,971 |
| 2026-03-16 | Taylor Ben R | -7,075 | $3.42 | $24,197 |
| 2026-03-09 | Gibson Christopher | -20,000 | - | - |
| 2026-03-09 | Gibson Christopher | -20,000 | - | - |
| 2026-03-09 | Gibson Christopher | +20,000 | - | - |
| 2026-03-09 | Khan Najat | -28,298 | $3.3451 | $94,660 |
| 2026-03-03 | Borgeson Blake | -170,000 | $3.46 | $588,200 |
| 2026-02-19 | Gibson Christopher | -40,000 | - | - |
| 2026-02-19 | Gibson Christopher | -40,000 | $3.46 | $138,400 |
| 2026-02-19 | Gibson Christopher | +40,000 | - | - |
| 2026-02-18 | Taylor Ben R | -13,426 | $3.08 | $41,352 |
| 2026-02-17 | Hallett David | -11,908 | $3.49 | $41,559 |
| 2026-02-17 | Gibson Christopher | -27,265 | $3.49 | $95,155 |
| 2026-02-17 | Taylor Ben R | -11,908 | $3.49 | $41,559 |
| 2026-02-17 | Khan Najat | -14,280 | $3.49 | $49,837 |
| 2026-02-06 | Khan Najat | -10,364 | $3.98 | $41,249 |
| 2026-02-06 | Khan Najat | +30,346 | - | - |
| 2026-02-06 | Khan Najat | +1,673,546 | - | - |
| 2026-02-06 | Taylor Ben R | -11,400 | $3.98 | $45,372 |
| 2026-02-06 | Taylor Ben R | +24,254 | - | - |
| 2026-02-06 | Taylor Ben R | +446,279 | - | - |
| 2026-02-06 | Hallett David | -11,400 | $3.98 | $45,372 |
| 2026-02-06 | Hallett David | +24,254 | - | - |
| 2026-02-06 | Hallett David | +502,064 | - | - |
| 2026-02-06 | Gibson Christopher | -10,364 | $3.56 | $36,896 |
| 2026-02-06 | Gibson Christopher | +30,346 | - | - |
| 2026-02-04 | Gibson Christopher | -40,000 | - | - |
| 2026-02-04 | Gibson Christopher | -40,000 | $4.12 | $164,800 |
| 2026-02-04 | Gibson Christopher | +40,000 | - | - |
| 2026-02-03 | Borgeson Blake | -220,000 | $4.2 | $924,000 |
| 2026-01-20 | Gibson Christopher | -40,000 | - | - |
| 2026-01-20 | Gibson Christopher | -40,000 | $4.47 | $178,800 |
| 2026-01-20 | Gibson Christopher | +40,000 | - | - |
| 2026-01-06 | Borgeson Blake | -220,000 | $4.36 | $959,200 |
| 2026-01-05 | Gibson Christopher | -60,000 | - | - |
| 2026-01-05 | Gibson Christopher | -20,000 | - | - |
| 2026-01-05 | Gibson Christopher | -40,000 | $4.25 | $170,000 |
| 2026-01-05 | Gibson Christopher | +60,000 | - | - |
| 2026-01-02 | Dar Zavain | +3,571 | - | - |
| 2026-01-02 | Li Dean Y | +2,381 | - | - |
| 2025-12-29 | Taylor Ben R | -21,383 | $4.18 | $89,381 |
| 2025-12-22 | Khan Najat | -124,403 | $4.4098 | $548,592 |
| 2025-12-19 | Gibson Christopher | -40,000 | - | - |
| 2025-12-19 | Gibson Christopher | -40,000 | $4.5 | $180,000 |
| 2025-12-19 | Gibson Christopher | +40,000 | - | - |
| 2025-12-15 | Taylor Ben R | -7,057 | $4.33 | $30,557 |
| 2025-12-04 | Gibson Christopher | -60,000 | - | - |
| 2025-12-04 | Gibson Christopher | -20,000 | - | - |
| 2025-12-04 | Gibson Christopher | -40,000 | $4.63 | $185,200 |
| 2025-12-04 | Gibson Christopher | +60,000 | - | - |
| 2025-12-02 | Borgeson Blake | -220,000 | $4.37 | $961,400 |
| 2025-11-25 | Taylor Ben R | -2,271 | $4.03 | $9,152 |
| 2025-11-19 | Gibson Christopher | -40,000 | - | - |
| 2025-11-19 | Gibson Christopher | -40,000 | $4.16 | $166,400 |
| 2025-11-19 | Gibson Christopher | +40,000 | - | - |
| 2025-11-17 | Khan Najat | -17,584 | $4.14 | $72,798 |
| 2025-11-17 | Gibson Christopher | -40,390 | $4.14 | $167,215 |
| 2025-11-17 | Taylor Ben R | -11,908 | $4.14 | $49,299 |
| 2025-11-05 | Khan Najat | +169,851 | - | - |
| 2025-11-05 | Khan Najat | +84,925 | - | - |
| 2025-11-04 | Gibson Christopher | -60,000 | - | - |
| 2025-11-04 | Gibson Christopher | -20,000 | - | - |
| 2025-11-04 | Gibson Christopher | -40,000 | $5.21 | $208,400 |
| 2025-11-04 | Gibson Christopher | +60,000 | - | - |
| 2025-10-23 | Gibson Christopher | -100,000 | - | - |
| 2025-10-23 | Gibson Christopher | -100,000 | $5.7 | $570,000 |
| 2025-10-23 | Gibson Christopher | +100,000 | - | - |
| 2025-10-10 | Gibson Christopher | -120,000 | - | - |
| 2025-10-10 | Gibson Christopher | -20,000 | - | - |
| 2025-10-10 | Gibson Christopher | -100,000 | $6.04 | $604,000 |
| 2025-10-10 | Gibson Christopher | +120,000 | - | - |